Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA. Zamagni C, et al. Endocr Relat Cancer. 2009 Dec;16(4):1241-9. doi: 10.1677/ERC-08-0342. Epub 2009 Sep 11. Endocr Relat Cancer. 2009. PMID: 19749010
Third national surgical consensus conference of the Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant chemotherapy: The difficulty in reaching a consensus.
Schiavone A, Ventimiglia F, Zarba Meli E, Taffurelli M, Caruso F, Gentilini OD, Del Mastro L, Livi L, Castellano I, Bernardi D, Minelli M, Fortunato L; ANISC Collaborative Group. Schiavone A, et al. Eur J Surg Oncol. 2024 Jul;50(7):108351. doi: 10.1016/j.ejso.2024.108351. Epub 2024 Apr 24. Eur J Surg Oncol. 2024. PMID: 38701582
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Among authors: zamagni c. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study.
Cortesi L, Cortesi G, Venturelli M, Marcheselli L, Toss A, Barbieri E, Tamburrano F, Musolino A, De Giorgi U, Bisagni G, Arcangeli V, Zamagni C, Cavanna L, Dominici M. Cortesi L, et al. Among authors: zamagni c. Eur J Surg Oncol. 2024 Oct;50(10):108603. doi: 10.1016/j.ejso.2024.108603. Epub 2024 Aug 12. Eur J Surg Oncol. 2024. PMID: 39154430
CA-549 serum levels in breast cancer monitoring.
Zamagni C, Martoni A, Cacciari N, Bellanova B, Vecchi F, Pannuti F. Zamagni C, et al. Int J Biol Markers. 1992 Oct-Dec;7(4):217-21. doi: 10.1177/172460089200700402. Int J Biol Markers. 1992. PMID: 1491176
174 results